Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.
about
Pediatric lymphomas and histiocytic disorders of childhoodHodgkin lymphoma--a survey of children and adolescents treated in Sweden 1985-2009.A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.Prognostic Value of FDG-PET, Based on the Revised Response Criteria, in Patients with Malignant Lymphoma: A Comparison with CT/MRI Evaluations, Based on the International Working Group/Cotswolds Meeting Criteria.Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Emerging immunotherapy in pediatric lymphoma.Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.Treatment of EBV-associated nodular sclerosing Hodgkin lymphoma in a patient with ataxia telangiectasia with brentuximab vedotin and reduced COPP plus rituximab.Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: the Memorial Sloan Kettering Cancer Center experience.Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care.
P2860
Q34605894-D61DB033-581E-49AB-8F28-B9446D803791Q34664424-1586FE3F-650B-4FAD-95CE-6A5B4F16EF69Q35772357-920E9908-3925-4236-BEAD-1AD30128792AQ37077176-403FB3A0-E832-4A78-AA37-679AA842430FQ37412853-A8458335-103F-4827-86D6-5CC3484D490EQ38643300-B09FB553-A0E0-45FC-8C95-3DCBCF1D7317Q38652326-83386906-4AB5-4A42-8A9B-7F18BDE71AF7Q39193590-4DEF5C36-3DD6-4495-9100-E477206435DBQ41141171-A7EC35EE-69B8-4095-AAD1-5D7C4FE772E5Q46379382-79EF1B10-109A-48F8-BA1F-30B69A7AB75CQ48548248-EE35C4DD-8E9F-4D2C-9535-37906390C1D3Q52722711-9B6F7709-C9A7-4115-BF6E-86B4DE659E41
P2860
Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.
@en
type
label
Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.
@en
prefLabel
Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.
@en
P2093
P2860
P356
P1476
Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.
@en
P2093
Burton Appel
COG Hodgkin Lymphoma Committee
David Hodgson
Frank G Keller
Kara M Kelly
Peter D Cole
Terzah Horton
P2860
P304
P356
10.1002/PBC.24423
P577
2012-12-19T00:00:00Z